Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We would like to congratulate Dr Luke Jostins-Dean on being awarded a 5-year Sir Henry Dale fellowship, joint funded by the Wellcome Trust and Royal Society, entitled ‘combining genetics and high-resolution cell phenotyping to map pathways underlying inflammatory bowel disease’.

Inflammatory bowel disease (IBD) is a term mainly used to describe two conditions; Crohn’s disease and ulcerative colitis which together affect more than 300,000 people in the UK. The ultimate aims of Luke’s project are to identify cell types and immune phenotypes that underlie IBD genetic risk and to understand how these affect disease prognosis. This research will be conducted using novel statistical methodology and experimental approaches such as single-cell RNA sequencing and mass cytometry. The project will make use of Oxford’s extensive patient cohorts, and Luke will work with clinicians and experimentalists throughout the Medical Sciences Division to link genotype to immune phenotype at scale.

Commenting on his award Luke said “I am incredibly excited to begin this project. Throughout my career I have identified over a hundred genetic risk variants for IBD, but this project will allow me to dig into what effect these variants actually have on the human immune system. Understanding the genetics of IBD will require combining statistical Big Data science with detailed molecular immunology, and this generous support from the Wellcome Trust and the Royal Society will allow us to generate the data and forge the collaborations we need to make this a reality”.

Luke will start his fellowship on 8th January 2018 and he will be based in the Kennedy, with a secondary affiliation to the Oxford Big Data Institute (BDI). Luke will collaborate with the growing number of computational researchers at the Kennedy Institute, including Dr Steve Sansom.

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.

World Osteoporosis Day 2022

A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.